RNN

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN: RNN) is flying early on in the market this morning, and for good reason. The company announced a new collaboration with Merck (MRK) that’s clearly proving to be a point of excitement for investors. Today, we’ll talk about: The collaboration; what we’re seeing from RNN as a result; and what we’ll … Read more

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN: RNN) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company reported data with regard to a key clinical trial, exciting investors and sending the stock screaming for the top. Today, we’ll talk about the data that was released, what we’re seeing from RNN, … Read more

Rexahn Pharmaceuticals, Inc. (NYSEMKT: RNN) is having an overwhelmingly strong day in the market today. While no new news has been released today, a quick look on StockTwits tells the whole story. At the end of the day, investors are excited, as the company’s flagship candidate is quickly making its way to its next data … Read more

Rexahn Pharmaceuticals, Inc. (NYSEMKT: RNN) is having an overwhelmingly rough day in the market today, and for good reason. The company announced that it would be moving forward with a reverse stock split, leading to fear among investors and declines in the stock. As is usually the case, our partners at Trade Ideas were the … Read more

Rexahn Pharmaceuticals, Inc. (NYSEMKT: RNN) Rexahn Pharmaceuticals offered investors a bit of insight into Phase 1 studies of its cancer fighting compounts known as Supinoxin and RX-3117. Overall, the data presented was positive. Today, we’ll talk about what we saw from the data, how the market reacted to the news, and what we can expect … Read more